Nucleic acid molecule encoding human defensin, method for preparing human defensin, and use
By optimizing the recombinant expression vector and purification method, the problem of expressing human defensins in Escherichia coli was solved, and the preparation of high-purity human defensins was achieved, which is suitable for anti-infection and tissue regeneration.
Patent Information
- Application Number
- PCT/CN2026/088225
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-04-02
- Publication Date
- 2026-11-19
AI Technical Summary
In existing technologies, human defensins are difficult to express in Escherichia coli, are prone to misfolding to form inclusion bodies, and have low refolding efficiency, resulting in low expression yield and activity of functional proteins, making large-scale production and application difficult.
By optimizing the pET-32a(+) vector framework, a recombinant expression vector was constructed. Using E. coli Origami competent cells, combined with protein assays and SDS-PAGE gel electrophoresis, the Trx-hBD-3 fusion protein was expressed and purified by enterokinase cleavage to obtain high-purity human defensin.
It improves the stability and purity of human defensins, reduces losses during expression, enhances protein solubility and activity, and is suitable for large-scale production, applicable to fields such as anti-infection, wound healing and tissue regeneration.
Smart Images

Figure CN2026088225_19112026_PF_FP_ABST
Abstract
Description
A nucleic acid molecule encoding human defensin, a method for preparing human defensin, and its applications. Technical Field
[0001] This application belongs to the fields of genetic engineering, bioengineering and biomedicine, and relates to a nucleic acid molecule encoding human defensin, a method for preparing human defensin and its application. Background Technology
[0002] Human beta-defensin 3 (hBD-3) is a naturally occurring antimicrobial peptide in the human body, belonging to the beta-defensin family. These peptides primarily participate in the body's innate immunity, fighting infection by directly killing microorganisms and regulating the immune system. hBD-3 possesses broad-spectrum antimicrobial activity, effectively combating bacteria (including Gram-positive and Gram-negative bacteria) and fungi, and also inhibiting certain viruses (such as human immunodeficiency virus, HIV). hBD-3 exerts its antimicrobial effect by disrupting the cell membranes of pathogens. It interacts with the anionic membranes of pathogens, leading to cell membrane rupture and pathogen death.
[0003] Due to its powerful antibacterial, immunomodulatory, and tissue regeneration functions, hBD-3 has been widely studied for its applications in anti-infective therapy, wound healing promotion, and oral mucosa and vaginal regeneration. With the increasing severity of antimicrobial resistance, hBD-3 represents a promising research direction for alternative antibiotics or adjuvant therapy. In summary, hBD-3, with its powerful antibacterial and immunomodulatory effects, as well as its unique advantages in promoting tissue regeneration and reducing induced resistance, has become an important focus of future biomedical research. However, human defensins are present in low concentrations in organisms, difficult to extract, and chemical synthesis methods are costly. Therefore, using genetic engineering is an economical and effective way to produce defensins on a large scale. However, when expressing the complex eukaryotic protein hBD-3, it is prone to misfolding and inclusion body formation in E. coli, resulting in low refolding efficiency and low expression yield and activity of functional proteins. Therefore, the preparation of human defensins using prokaryotic recombinant methods is difficult, and the antibacterial activity of recombinant peptides is also hard to guarantee. This is currently a key factor restricting the recombinant preparation of defensins.
[0004] Therefore, there is an urgent need to provide an effective method for preparing recombinant defensins and their new applications. Summary of the Invention
[0005] This application provides a nucleic acid molecule encoding human defensin, a method for preparing human defensin, and its applications. This application optimizes the recombinant expression vector of human defensin based on the pET-32a(+) vector framework. Through transformation into competent *E. coli* cells (Origami), and by protein trials and SDS-PAGE gel electrophoresis to explore expression conditions, it was found that the fusion protein Trx-hBD-3 was successfully expressed in the supernatant by the human defensin and the pET-32a(+) recombinant expression vector. The fusion protein was cleaved by enterokinase, and then purified according to the expressed protein tag to successfully obtain human defensin. The recombinant human defensin of this application has multiple functions, including antibacterial activity and promotion of collagen expression, and has potential application value.
[0006] In a first aspect, this application provides a nucleic acid molecule encoding a human defensin, wherein the nucleic acid sequence of the nucleic acid molecule includes any of the following:
[0007] (1) A sequence as shown in SEQ ID NO.2;
[0008] (2) A nucleic acid sequence encoding a human defensin obtained by substituting, deleting, or adding one or more nucleotides to the sequence shown in SEQ ID NO.2; or
[0009] (3) A nucleic acid sequence that has at least 80% sequence homology with the nucleic acid sequence described in (1) or (2) and has the same or similar function.
[0010] The method described in this application uses nucleic acid molecules encoding human defensins to construct a recombinant expression vector that can recombinantly express human defensin hBD-3, releasing the recombinant fusion protein into the culture supernatant, which facilitates protein purification. The recombinant human defensin obtained by this method has tissue regeneration function, providing a new active molecule for the development of novel drugs.
[0011]
[0012] Secondly, this application provides a vector containing the nucleic acid molecule encoding human defensin as described in the first aspect.
[0013] Thirdly, this application provides a recombinant cell containing a nucleic acid molecule encoding a human defensin as described in the first aspect or a vector as described in the second aspect.
[0014] Fourthly, this application provides a method for recombinant preparation of human defensins, the method comprising the following steps:
[0015] (1) Construct a recombinant plasmid containing the nucleic acid molecule encoding human defensin as described in the first aspect, transform it into competent cells, and obtain a human defensin-expressing strain after culturing;
[0016] (2) Recombinant human defensin fusion protein was obtained by inducing human defensin expression in strains using an inducer;
[0017] (3) Purify the recombinant human defensin fusion protein obtained in step (2).
[0018] In this application, the nucleic acid molecule encoding human defensin can be obtained by chemical synthesis or PCR.
[0019] Preferably, the construction of the recombinant plasmid containing the nucleic acid molecule encoding human defensin described in the first aspect in step (1) includes: synthesizing a nucleic acid molecule encoding human defensin; modifying and replacing the his tag and thrombin restriction site located after the lysing tag TrxA in the plasmid with a highly specific tag and an amino acid residue-free restriction site; removing the tag used for high protein purification and the amino acid residue-free tag; adding 5' (MscI) and 3' (XhoI); and cloning the nucleic acid molecule encoding human defensin into the vector to obtain the recombinant plasmid.
[0020] Preferably, the highly specific tag includes twins-strep.
[0021] Preferably, the amino acid residue-free enzyme cleavage site includes an enterokinase cleavage site.
[0022] Preferably, the purification in step (3) includes ultrafiltration and enzymatic digestion.
[0023] Preferably, the enzymatic digestion includes: rinsing the human defensin fusion protein bound to the purification column with an enzymatic digestion buffer, resuspending the human defensin fusion protein purification column with an enzymatic digestion buffer, adding enterokinase containing a His tag, digesting overnight, collecting the flow-through, removing the enterokinase, centrifuging the flow-through, and obtaining human defensin.
[0024] It is understood that the expression systems in this application also include expression systems known to those skilled in the art, such as plant expression systems, insect cell expression systems (Baculovirus expression), mammalian cell expression systems, cell-free protein expression systems, or yeast expression systems.
[0025] Fifthly, this application provides a human defensin, which is prepared by the recombinant preparation method of the human defensin described in the fourth aspect.
[0026] It is understood that human defensins and their functionally equivalent mutants and derivatives (such as modified versions and pharmaceutically acceptable salts) are all within the scope of protection of this application.
[0027] In a sixth aspect, this application provides a fusion protein containing the human defensin described in the fifth aspect, the fusion protein containing the human defensin and collagen-binding domain as described in claim 7, wherein the human defensin and collagen-binding domain in the fusion protein are linked by a flexible linker peptide, and the collagen-binding domain is located at the N-terminus or C-terminus of the fusion protein.
[0028] Preferably, the amino acid sequence of the fusion protein includes the sequence shown in SEQ ID NO.3.
[0029] In this application, the fusion protein can specifically bind to the collagen membrane scaffold and achieve continuous release. The collagen membrane scaffold includes scaffold materials containing type I collagen, such as decellularized matrix collagen scaffolds, collagen / gelatin electrospun membrane scaffolds, or gelatin methacryloyl hydrogel scaffolds.
[0030] In this application, the fusion protein can be used to prepare biomedical materials, which contain the fusion protein described in this application and a decellularized collagen membrane.
[0031] In this application, the method for preparing the biomedical material includes the following steps:
[0032] (1) Construct an expression vector encoding the fusion protein and express it in host cells;
[0033] (2) Purification to obtain the fusion protein;
[0034] (3) Apply the fusion protein solution to the decellularized collagen membrane to bind it and form a sustained-release system.
[0035] The decellularized collagen membrane described in this application can sustainably release the fusion protein in PBS for more than 7 days.
[0036]
[0037] Preferably, the nucleic acid sequence encoding the fusion protein includes any one of the following:
[0038] (1) A sequence as shown in SEQ ID NO.4;
[0039] (2) A nucleic acid sequence encoding a human defensin obtained by substituting, deleting, or adding one or more nucleotides to the sequence shown in SEQ ID NO.4; or
[0040] (3) A nucleic acid sequence that has at least 80% sequence homology with the nucleic acid sequence described in (1) or (2) and has the same or similar function.
[0041]
[0042] In a seventh aspect, this application provides the use of the nucleic acid molecule encoding human defensin described in the first aspect, the vector described in the second aspect, the recombinant cell described in the third aspect, or the human defensin described in the fifth aspect in the preparation of antibacterial, anti-inflammatory, or tissue regeneration products.
[0043] Preferably, the product includes any one of a drug, a healing material, or a medical device coating.
[0044] In this application, molecular biology experiments clarified the mechanism by which hBD-3 acts on fibroblasts. It primarily reduces TGF-β1 production by inhibiting the binding of TSP-1 to CD36 and selectively acts on both normal and activated fibroblasts, thereby reducing scarring and providing a new mechanistic basis for tissue repair. This novel function has broad applicability in different types of models (such as wound healing models and mucosal injuries). hBD-3 has shown significant effects in wound healing (skin trauma, burns) and tissue repair (mucosal injuries, corneal repair). It has potential applications in regenerative medicine (such as postoperative tissue repair and graft healing) and aesthetic medicine (such as skin regeneration).
[0045] The recombinant hBD-3 protein prepared in this application can be applied not only to animal models but also to fibroblast models subjected to ultraviolet (UV) radiation, providing new insights into the molecular basis of UV-induced skin damage and potential strategies for skin repair and photoprotection.
[0046] Prolonged or excessive ultraviolet (UV) radiation exposure can lead to a range of skin changes, including inflammation, DNA damage, oxidative stress, and extracellular matrix (ECM) remodeling, ultimately resulting in photoaging, pigmentary disorders, and even tumorigenesis. Dermal fibroblasts are the main ECM-producing cells in the dermis and play a crucial role in maintaining skin structure and function. Fibroblasts are highly sensitive to UV-induced stress responses and undergo significant phenotypic and functional changes after irradiation. Low-dose UV radiation can induce stress activation, mimicking the damage to the dermis caused by UV rays in sunlight. Therefore, UV-treated fibroblast models provide a valuable platform for exploring the cellular and molecular mechanisms of UV-induced skin damage and evaluating the efficacy of photoprotective agents.
[0047] The recombinant hBD-3 protein obtained in this application can achieve functions such as extracellular matrix remodeling, angiogenesis, scar inhibition and cell proliferation. In addition, it has other potential applications such as promoting skin repair, enhancing skin barrier function and improving skin appearance.
[0048] hBD-3 can be prepared in various drug forms, including topical ointments, sprays, and injections.
[0049] Gene-engineered expression systems and modified versions of hBD-3 (such as functional mutants) can be used in the development of therapeutic products.
[0050] In this application, hBD-3 exhibits strong thermal stability and biological activity, maintaining its function in various environments. As an endogenous protein, hBD-3 demonstrates high safety and a low risk of toxic side effects.
[0051] Compared with the prior art, this application has the following beneficial effects:
[0052] (1) The method of this application significantly improves the stability of hBD-3 by fusing with Trx A, and reduces the loss caused by degradation during expression.
[0053] (2) The recombinant expression vector constructed by the method of this application can recombinantly express human defensin hBD-3, so that the recombinant fusion protein is released into the culture supernatant, which facilitates protein purification. By fusing the Strep tag, the protein purification process can be significantly simplified by using affinity purification technology, and the number of purification times can be reduced by on-column enzyme digestion, thereby improving the yield and purity of the target protein. The presence of the fusion tag enables non-specific proteins to be effectively removed during the purification process, resulting in high-purity hBD-3.
[0054] (3) The method of this application improves the solubility of the protein and reduces the formation of inclusion bodies. Since hBD-3 contains three pairs of disulfide bonds, it is easy to form inclusion bodies during expression. By fusing with certain highly soluble proteins (Trx A), the soluble expression of hBD-3 can be significantly improved, the formation of insoluble inclusion bodies can be reduced, and the active yield of the protein can be increased. In addition, by double mutation of thioredoxin reductase (trxB) and glutathione reductase (gor), the intracellular reduction pathway is disrupted, the oxidative environment is enhanced, and the formation of disulfide bonds is promoted. This mutation makes the cytoplasm closer to the oxidative state of eukaryotic cells, which is suitable for expressing proteins that depend on the correct disulfide bonds. Origami strains are often used in combination with pET32a(+) vectors carrying thioredoxin (Trx) tags. The Trx tag acts as a molecular chaperone, further assisting protein folding and inhibiting aggregation, significantly improving the active expression efficiency of disulfide bond proteins.
[0055] (4) This application is the first to discover that hBD-3 reduces the production of TGF-β1 by inhibiting the binding of TSP-1 and CD36, thereby reducing the production of scars, and can selectively act on normal and activated fibroblasts, thus having broad application prospects in tissue repair and regenerative medicine. The recombinant human defensin obtained by the method of this application is beneficial to the development of multifunctional fusion proteins. By designing fusion with other bioactive proteins, the multifunctional application of hBD-3 can be realized, such as in the fields of anti-infection coatings, wound dressings and tissue engineering scaffolds.
[0056] (5) The method of this application is suitable for large-scale production, economical and efficient. Through gene recombination technology, hBD-3 protein can be produced on a large scale in bacteria or other microorganisms. It is low-cost and suitable for industrial application.
[0057] (6) The method of this application is easy to operate, and the optimization of the fusion label and expression system makes the method highly operable in both laboratory and production scale. Attached Figure Description
[0058] Figure 1 is a schematic diagram of the plasmid constructed in this application.
[0059] Figure 2 shows the whole plasmid assay results.
[0060] Figure 3 shows the SDS-PAGE gel electrophoresis results in Example 2.
[0061] Figure 4 shows the results of the Western blot experiment in Example 2.
[0062] Figure 5 shows the results of the Western blot experiment in Example 3.
[0063] Figure 6 shows the antibacterial detection results in Example 4.
[0064] Figure 7 shows the qPCR results in Example 5.
[0065] Figure 8 shows the agarose gel electrophoresis results in Example 5.
[0066] Figure 9A is a heatmap of fibroblast phenotype genes after ultraviolet irradiation.
[0067] Figure 9B is a heatmap of regeneration and scar gene expression after hBD-3 treatment.
[0068] Figure 9C is a heatmap of angiogenic gene expression after hBD-3 treatment.
[0069] Figure 10 shows the expression results of TGF-β1.
[0070] Figure 11 shows the results of wound healing.
[0071] Figure 12 shows the statistical results of wound healing area.
[0072] Figure 13 shows the results of H&E staining.
[0073] Figure 14 shows the protein release results in Example 8. Detailed Implementation
[0074] To further illustrate the technical means and effects adopted in this application, the following description, in conjunction with embodiments and accompanying drawings, will provide further details. It is understood that the specific embodiments described herein are merely for explaining this application and not for limiting it.
[0075] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.
[0076] Example 1
[0077] Construction of the engineered strain Origami-pET32a(+) / hBD-3.
[0078] 1. Codon optimization
[0079] The full sequence of human β-defensin 3 (hBD-3) was predicted from the NCBI gene database. It has three disulfide bonds linked by Cys1-Cys5, Cys2-Cys4, and Cys3-Cys6 connections. The amino acid sequence of the mature polypeptide is as follows:
[0080]
[0081] The optimized coding nucleic acid sequence obtained through E. coli codon optimization is as follows:
[0082]
[0083] 2. Construction of the pET32a(+) / hBD-3 recombinant plasmid
[0084] The gene hBD-3 was synthesized. The his tag and thrombin restriction site located after the lysis tag TrxA in the plasmid were replaced with twins-strep and enterokinase restriction sites through genetic engineering. This was used for high-level protein purification and tag removal without amino acid residues. 5' (MscI) and 3' (XhoI) were added. The gene was cloned into the vector pET32a(+) (Ampicillin) through 5'MscI and 3'XhoI (using recombination method) to construct the plasmid, as shown in Figure 1.
[0085] 3. Constructing the engineered expression strain Origami-pET32a(+) / hBD-3
[0086] (1) Preparation of competent cells: Escherichia coli Origami was prepared into competent cells using a one-step competent bacterial preparation kit (Beyotime).
[0087] (2) Transformation experiment: pET32a(+) / hBD-3 plasmid was transformed into Escherichia coli Origami competent cells using conventional methods. The transformation product was inoculated on LB plates containing ampicillin and cultured overnight. On the second day, positive colonies were picked and cultured for full plasmid pass identification.
[0088] 4. Experimental Results
[0089] The whole plasmid was identified as having the correct mature hBD-3 peptide sequence inserted into the plasmid and without any mutations (Figure 2).
[0090] Example 2
[0091] Induced expression and identification of hBD-3 recombinant protein.
[0092] 1. Inducible expression of recombinant hBD-3 protein
[0093] The glycerol-preserved expression strain Origami-pET32a(+) / hBD-3 was inoculated into 5 mL of LB / AMP liquid medium and cultured overnight at 37°C with shaking. Then, 5 mL of the bacterial culture was re-inoculated into 1 L of LB / AMP liquid medium at a 1:200 ratio and cultured at 37°C with shaking at 200 rpm for 2 h until the cells reached the logarithmic growth phase (OD200). 600 =0.4~0.6), as a positive control, no IPTG was added, while the rest were added with IPTG to a final concentration of 0.2 mM. The cells were then incubated overnight at 18°C. After centrifugation to remove the supernatant, the bacterial cells were resuspended in loading buffer (20 mM Tris, 150 mM NaCl, pH=7.6) (1 g of bacteria to 9 mL of loading buffer). Hammer Supercrystallization Broth (ACE) was added to 1 / 9 of the bacterial resuspension volume, and the mixture was stirred or vortexed until homogeneous. The sample was lysed at 25°C for 10 min, and the whole solution was retained. Subsequently, the mixture was centrifuged at 8000 rpm at 4°C for 20 min, and the supernatant was collected. The precipitate was resuspended in an equal volume of loading buffer.
[0094] 2. SDS-PAGE analysis
[0095] Add the above samples (total solution, precipitate, supernatant) to 4×LDS protein loading buffer, boil at 100℃ for 10 min, and cool for later use. Using an ACE gradient gel (4-20%), load 30 μL of the prepared protein sample and 10 μL of protein marker into the wells. Electrophoresis conditions: 160 V voltage in the gel, electrophoresis time approximately 40 min. After electrophoresis, peel off the gel, add Coomassie Brilliant Blue staining solution, and stain for 1 h. Rinse several times with Milli-Q water, then destain three times on a shaker with elution buffer (50 mL methanol + 100 mL glacial acetic acid + 850 mL Milli-Q water) until the protein bands are clear. Record the electrophoresis results using a gel imaging system.
[0096] 3. Western blot identification of proteins
[0097] Add 30 μL of the above sample (total solution, precipitate, supernatant) to 10 μL of 4×LDS protein electrophoresis loading buffer and boil for 10 min. Perform SDS-PAGE electrophoresis. After electrophoresis, transfer the protein bands on the gel to a PVDF membrane and incubate them with rabbit polyclonal antibody hBD-3 (1:1000) and goat anti-rabbit IgG antibody (1:4000) respectively. Develop with ECL luminescent solution and save the images.
[0098] 4. Experimental Results
[0099] Results of hBD-3 recombinant protein induction expression: SDS-PAGE gel electrophoresis results showed that after IPTG induction, the Origami-pET32a(+) / hBD-3 prokaryotic expression engineered bacteria showed a band of hBD-3 recombinant protein expression at approximately 25 kDa, while the target protein was not significantly expressed without IPTG induction. SDS-PAGE gel electrophoresis results after hBD-3 recombinant protein lysis (Figure 3) showed that the protein obtained after IPTG induction was mostly soluble and did not require denaturation or renaturation treatment.
[0100] Western blot identification results of recombinant hBD-3 protein: The results of the Western blot experiment showed that when rabbit polyclonal antibody hBD-3 was used as the primary antibody, Origami-pET32a(+) / hBD-3 had a protein blot band of about 25 kDa (Figure 4).
[0101] Example 3
[0102] Purification and enzymatic digestion of hBD-3 recombinant protein.
[0103] 1. Protein purification
[0104] The supernatant of the bacterial culture obtained in Example 2 was used to purify the expressed hBD-3 recombinant protein according to the instructions of the Strep purification column from Kangti Life Company, without elution.
[0105] 2. Enzyme digestion of recombinant proteins
[0106] On-column digestion: The hBD-3 recombinant protein bound to the purification column was repeatedly washed with digestion buffer, and then the hBD-3 recombinant protein purification column was resuspended with digestion buffer. Enterokinase (containing a His tag, final concentration 0.2 U / mL) was added, mixed, and digested overnight at 25°C. The flow-through was collected, and enterokinase was removed according to the instructions of the His purification magnetic beads from Yisheng Company. Subsequently, the flow-through was centrifuged in an ultrafiltration centrifuge tube (3 kDa) at 12000×g for 20-40 min. The liquid in the inner tube was discarded, and the liquid in the inner tube was replenished with sterile Milli-Q water. The centrifugation was repeated 2-3 times to remove salts. Finally, the liquid in the inner tube was collected, and quantification was performed using a BCA protein quantification kit. The quantified recombinant hBD-3 peptide was identified by SDS-PAGE electrophoresis and Western blotting.
[0107] 3. Experimental Results
[0108] SDS-PAGE electrophoresis results of recombinant hBD-3 peptide: After enterokinase digestion, the tag protein was completely removed. The digestion product was purified, desalted, and concentrated to obtain hBD-3 (approximately 8 kDa). Western blot identification results of recombinant hBD-3: The Western blot results of recombinant hBD-3 protein showed a protein blot band of approximately 8 kDa, which is consistent with the theoretical value (Figure 5).
[0109] Example 4
[0110] Anti-Escherichia coli activity of recombinant hBD-3.
[0111] 1. Preparation of bacteria
[0112] The revived E. coli strain was plated on an agar plate and incubated overnight. Single colonies were then picked and inoculated onto LB broth for further culture, adjusting the E. coli concentration to 10⁻⁶. 7 CFU / mL, blow well to prepare a bacterial suspension.
[0113] 2. Detection of antibacterial activity
[0114] The antibacterial activity of hBD-3 was detected using the agar plate diffusion method. A suspension of *E. coli* (10...) was prepared... 7CFU / mL (0.1 mL) was inoculated onto solid agar medium. Sterile filter paper discs (6 mm in diameter) saturated with hBD-3 (20 μg / mL) and blank LB were used as controls. The filter paper discs were placed on solid agar medium and incubated at 37°C for 24 h. The diameter of the growth inhibition zone was measured (Figure 6), indicating that the recombinant hBD-3 of this application can effectively inhibit bacteria.
[0115] Example 5
[0116] Application of hBD-3 in activating fibroblasts.
[0117] 1. Constructing and activating fibroblasts
[0118] Fibroblasts were activated by ultraviolet (UV) irradiation. Cells were irradiated with UVC (shortwave) for 2 min, passaged, and then irradiated for another 2 min. After two irradiations, normal fibroblasts in the control group and activated fibroblasts in the irradiated group were obtained. qPCR and Western blotting experiments were performed to identify the fibroblast phenotype.
[0119] 2. hBD-3 intervention in different fibroblasts
[0120] 5000 NIH3T3 cells were evenly seeded per well in a 96-well plate. After 12 h of culture, 1 μg / mL of hBD-3 was added to each experimental group. Cells were collected after 24 h and transcriptomic sequencing was performed. N represents normal fibroblasts, S represents activated fibroblasts, and NH and SH represent normal fibroblasts + hBD-3 and activated fibroblasts + hBD-3, respectively.
[0121] 3. Experimental Results
[0122] qPCR (Figure 7) and Western blotting (Figure 8) experiments verified the high expression of α-SMA and CD36, demonstrating the successful construction of activated fibroblasts.
[0123] Transcriptomic analysis of UV-irradiated fibroblasts revealed a significant increase in genes associated with the activated fibroblast phenotype, indicating successful construction of activated fibroblasts (Figure 9A). Further analysis showed that hBD-3 intervention resulted in normal fibroblasts producing more proteins related to cell migration, adhesion, and actin polymerization, while activated fibroblasts produced fewer of these proteins (Figure 9B). This suggests that hBD-3 can selectively intervene in fibroblasts to promote tissue regeneration. Furthermore, transcriptomic analysis revealed upregulation of pro-angiogenic factor-related genes in activated fibroblasts, a trend consistent with hBD-3 intervention (Figure 9C).
[0124] Example 6
[0125] Application of hBD-3 in scar suppression.
[0126] 1. Mechanism Exploration
[0127] Since TSP-1 levels significantly increase after injury, and it can bind to CD36 to produce TGF-β1, this experiment introduced TSP-1 (20 μg / mL) and hBD-3 (10 μg / mL) into normal fibroblasts and activated fibroblasts, and observed the production of TGF-β1.
[0128] 2. Experimental Results
[0129] The results showed that TGF-β1 was highly expressed in activated fibroblasts, and TSP-1-induced activated fibroblasts also showed high TGF-β1 expression. hBD-3 reduced TGF-β1 expression in TSP-1-induced activated fibroblasts, while hBD-3 treatment did not significantly affect TGF-β1 expression in TSP-1-induced normal fibroblasts (Figure 10).
[0130] Example 7
[0131] Application of hBD-3 in skin wound healing in rats.
[0132] A thermosensitive hydrogel was prepared using poloxamer 188, poloxamer 407, and hydroxypropyl methylcellulose. hBD-3 at a concentration of 1 μg / mL was added, and the gel was administered once daily to a rat skin model with a wound diameter of 5 mm. In the rat skin wound model, application of hBD-3 (1 µg / mL) for 7 days significantly accelerated wound healing (Figures 11 and 12). H&E staining revealed rapid proliferation of epithelial tissue in the hBD-3 group, indistinguishable from normal tissue, with reduced granulation tissue. Masson staining showed that collagen production in the regenerated epithelium of the hBD-3 group was similar to that of normal tissue (Figure 13).
[0133] Example 8
[0134] The binding and release of CBD-hBD-3 fusion protein to collagen membrane (decellularized matrix collagen).
[0135] 1. Preparation of CBD-hBD-3 fusion protein
[0136] The preparation method is the same as that for the hBD-3 recombinant protein. Referring to Example 1, the amino acid sequence of the fusion protein CBD-hBD-3 is shown in SEQ ID NO.3. Through E. coli codon optimization, the optimized coding nucleic acid sequence is shown in SEQ ID NO.4.
[0137]
[0138]
[0139] 2. Binding of CBD-hBD-3 to decellularized matrix collagen
[0140] Different concentrations of CBD-hBD-3 (2.5 μg / cm) were used. 2 5 μg / cm 2 10 μg / cm 2 20 μg / cm 2 40 μg / cm 2 (This refers to the amount of CBD-hBD-3 co-incubated per square centimeter of decellularized matrix collagen.) The solution was co-incubated with decellularized matrix collagen overnight at four times, and the content of remaining CBD-hBD-3 in the supernatant was detected to calculate the amount of CBD-hBD-3 bound to decellularized matrix collagen.
[0141] 3. Release of CBD-hBD-3 from decellularized matrix collagen
[0142] The maximum concentration of CBD-hBD-3 that can be bound to decellularized matrix collagen is 26.69 ± 1.19 μg / cm³. 2 (The amount of CBD-hBD-3 co-incubated per square centimeter of decellularized matrix collagen) The solution was co-incubated with the collagen membrane for four overnight cycles. After washing three times with PBS, fresh PBS was added. The protein content in the supernatant was measured on days 1, 4, and 7, and the protein release over 7 days was calculated.
[0143] 4. Experimental Results
[0144] The results are shown in Figure 14. The maximum binding amount of decellularized matrix collagen was 26.69 ± 1.19 μg / cm³. 2 The cumulative release over seven days was 6.49 ± 0.63 μg, indicating that the fusion protein CBD-hBD-3 of this application can effectively bind to the collagen membrane (decellularized matrix collagen) and achieve sustained release.
[0145] In summary, this application constructs a recombinant expression vector capable of recombinantly expressing human defensin hBD-3, releasing the recombinant fusion protein into the culture supernatant, which facilitates protein purification. The recombinant human defensin obtained by the method of this application has tissue regeneration function, providing a new active molecule for the development of novel drugs.
[0146] The applicant declares that this application illustrates the detailed method of this application through the above embodiments, but this application is not limited to the above detailed method, that is, it does not mean that this application must rely on the above detailed method to be implemented. Those skilled in the art should understand that any improvements to this application, equivalent substitutions of the raw materials of this application's product, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of this application.
Claims
1. A nucleic acid molecule encoding a human defensin, wherein the nucleic acid sequence comprises any one of the following: (1) A sequence as shown in SEQ ID NO.2; (2) A nucleic acid sequence encoding a human defensin obtained by substituting, deleting, or adding one or more nucleotides to the sequence shown in SEQ ID NO.2; or (3) A nucleic acid sequence that has at least 80% sequence homology with the nucleic acid sequence described in (1) or (2) and has the same or similar function.
2. A vector containing a nucleic acid molecule encoding a human defensin as described in claim 1.
3. A recombinant cell containing the nucleic acid molecule encoding human defensin as described in claim 1 or the vector as described in claim 2.
4. A method for preparing recombinant human defensins, comprising the following steps: (1) Construct a recombinant plasmid containing the nucleic acid molecule encoding human defensin as described in claim 1, transform it into competent cells, and culture it to obtain a human defensin-expressing strain; (2) Recombinant human defensin fusion protein was obtained by inducing human defensin expression in strains using an inducer; and (3) Purify the recombinant human defensin fusion protein obtained in step (2).
5. The method for recombinant preparation of human defensin according to claim 4, wherein, The construction of a recombinant plasmid containing the nucleic acid molecule encoding human defensin as described in claim 1 in step (1) includes: synthesizing a nucleic acid molecule encoding human defensin; modifying and replacing the his tag and thrombin restriction site located after the lysing tag TrxA in the plasmid with a highly specific tag and an amino acid residue-free restriction site; removing the tag used for high protein purification and the amino acid residue-free tag; adding 5' (MscI) and 3' (XhoI); and cloning the nucleic acid molecule encoding human defensin into a vector to obtain a recombinant plasmid. The highly specific tag includes twins-strep; The amino acid residue-free enzyme cleavage sites include enterokinase cleavage sites.
6. The method for recombinant preparation of human defensin according to claim 4, wherein, The purification described in step (3) includes ultrafiltration and enzymatic digestion; The enzyme digestion includes: rinsing the human defensin fusion protein bound to the purification column with enzyme digestion buffer, resuspending the human defensin fusion protein purification column with enzyme digestion buffer, adding enterokinase containing the His tag, digesting overnight, collecting the flow-through, removing the enterokinase, centrifuging the flow-through, and obtaining human defensin.
7. A human defensin, prepared by the recombinant preparation method of the human defensin according to any one of claims 4-6.
8. A fusion protein comprising the human defensin and collagen-binding domains of claim 7, wherein the human defensin and collagen-binding domains in the fusion protein are linked by a flexible linker peptide, and the collagen-binding domains are located at the N-terminus or C-terminus of the fusion protein. in, The fusion protein can specifically bind to the collagen membrane scaffold and achieve continuous release; The collagen membrane scaffold includes any one of decellularized matrix collagen scaffold, collagen / gelatin electrospun membrane scaffold, or gelatin methacrylamide hydrogel scaffold. The amino acid sequence of the fusion protein includes the sequence shown in SEQ ID NO.3; The nucleic acid sequence encoding the fusion protein includes any of the following: (1) A sequence as shown in SEQ ID NO.4; (2) A nucleic acid sequence encoding a human defensin obtained by substituting, deleting, or adding one or more nucleotides to the sequence shown in SEQ ID NO.4; or (3) A nucleic acid sequence that has at least 80% sequence homology with the nucleic acid sequence described in (1) or (2) and has the same or similar function.
9. The use of the nucleic acid molecule encoding human defensin according to claim 1, the vector according to claim 2, the recombinant cell according to claim 3, or the human defensin according to claim 8 in the preparation of antibacterial, anti-inflammatory, or tissue regeneration products.
10. The application according to claim 9, wherein, The product includes any one of a drug, a healing material, or a medical device coating.
